Delivery Order SPE2DB24D1205-SPE2DB25FCZKL
- Not listed
- The Defense Logistics Agency awarded a $13,916.52 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 ml solution in unit-dose vials on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, competitively awarded contract (no set-aside used) calls for the pharmaceutical distributor to deliver the medication to its Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $1,973.31 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit-dose 3 mL vials on August 8, 2025, with completion targeted for August 11, 2025. This firm fixed-price contract represents a non-set-aside competitive award supporting federal medical procurement needs. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a primary...
- The Defense Logistics Agency awarded a delivery order valued at $12,881.25 to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 ml solution in unit dose vials on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order represents a pediatric or specialized pharmaceutical supply requirement fulfilled through competitive procurement with no set-aside designation. The place of performance is AmerisourceBergen's Corporate Office location in...
- The Defense Logistics Agency awarded a $1,973.31 delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 1, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Yupelri (roflumilast) 175 micrograms per 3 milliliters solution in unit dose 3-milliliter vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,587.44 and is scheduled for completion by August 11, 2025. The contract involves no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $2,261.31 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide YUPELRI 175 MCG/3 ML SOLUTION UD 3ML. This delivery order is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
- This is a $1,368.99 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for YUPELRI 175 MCG/3 ML SOLUTION UD 3ML, a prescription medication. The contract has an ultimate completion date of July 9, 2025 and is not set aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global...
- The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order valued at approximately $12,791 to Amerisourcebergen Drug Corporation for 4562158368 YUPELRI 175 MCG/3 ML SOLUTION UD 3ML. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is September 13-14, 2023. This delivery order was issued against an existing indefinite-delivery/indefinite-quantity contract vehicle held by...
- The Defense Logistics Agency Troop Support Medical awarded a $3,860.65 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 175 micrograms/3 milliliters of YUPELRI solution in 3 milliliter bottles. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The delivery order has a period of performance starting on September 20, 2023 through September 21, 2023. No major subcontractors or set aside designations were indicated. The...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $33,611.28, is for the supply of YUPELRI 175 MCG/3 ML SOLUTION UD 3ML, a pharmaceutical product. The contract has a firm fixed-price pricing type and an ultimate completion date of July 10, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZKLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Yupelri 175 mcg/3 mL solution in unit dose 3 mL vials, with a ceiling value of $8,823.72. This non-competitive delivery order was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract employs firm fixed price pricing and represents a routine pharmaceutical procurement supporting federal medical supply requirements. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, running through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs and other government healthcare systems worldwide. The Yupelri medication, a long-acting muscarinic antagonist used in respiratory treatment, exemplifies the specialized pharmaceutical commodities the company provides through its federal contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 8/11/25 |